Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (531-540 of 1,211) with videos related to

Pageof 122
Sort By:
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
American Heart Journal|October 11, 2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah, Chung-Lieh Hung, Sung Hee Shin, et al.
Circulation. Heart Failure|February 27, 2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) TrialScott D Solomon, Brian Claggett, Akshay S Desai, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 10, 2019
Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and deathDaniel Modin, Brian Claggett, Gunnar Gislason, et al.
European Journal of Heart Failure|April 17, 2023
Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failureKhawaja M Talha, Javed Butler, Stephen J Greene, et al.
JACC. Heart Failure|June 21, 2024
Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection FractionToru Kondo, Ross Campbell, Pardeep S Jhund, et al.
European Journal of Heart Failure|October 23, 2024
Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Circulation. Heart Failure|June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
European Journal of Heart Failure|May 16, 2023
Incremental prognostic value of biomarkers in PARADIGM-HFKirsty McDowell, Ross Campbell, Joanne Simpson, et al.
American Heart Journal|October 8, 2005
Prognostic use of echocardiography 1 year after a myocardial infarctionHicham Skali, Leonardo A M Zornoff, Marc A Pfeffer, et al.
Pageof 122

Showing results (531-540 of 1,211) with videos related to

Sort By:
Pageof 122
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
American Heart Journal|October 11, 2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah, Chung-Lieh Hung, Sung Hee Shin, et al.
Circulation. Heart Failure|February 27, 2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) TrialScott D Solomon, Brian Claggett, Akshay S Desai, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 10, 2019
Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and deathDaniel Modin, Brian Claggett, Gunnar Gislason, et al.
European Journal of Heart Failure|April 17, 2023
Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failureKhawaja M Talha, Javed Butler, Stephen J Greene, et al.
JACC. Heart Failure|June 21, 2024
Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection FractionToru Kondo, Ross Campbell, Pardeep S Jhund, et al.
European Journal of Heart Failure|October 23, 2024
Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Circulation. Heart Failure|June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
European Journal of Heart Failure|May 16, 2023
Incremental prognostic value of biomarkers in PARADIGM-HFKirsty McDowell, Ross Campbell, Joanne Simpson, et al.
American Heart Journal|October 8, 2005
Prognostic use of echocardiography 1 year after a myocardial infarctionHicham Skali, Leonardo A M Zornoff, Marc A Pfeffer, et al.
Pageof 122